Pre-made Mepolizumab benchmark antibody ( Whole mAb, anti-IL5 therapeutic antibody, Anti-EDF/IL-5/TRF Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-341
Pre-Made Mepolizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Mepolizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases|
|Conditions Approved||Asthma;Churg-Strauss syndrome;Hypereosinophilic syndrome|
|Conditions Active||Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis|
|Conditions Discontinued||Atopic dermatitis|